ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
Dr. Lal PathLabs discloses share transactions by designated persons and an employee welfare trust under PIT regulations.
Designated persons at Dr. Lal PathLabs Ltd disclosed three equity trades totaling Rs. 0.50 Crore, as mandated under Insider Trading regulations.
Designated persons of Dr. Lal PathLabs Ltd sold equity shares worth a combined ₹0.49 Crore via market sales.
Designated persons and the employee welfare trust of Dr. Lal PathLabs Ltd disclosed share transactions under PIT Regulations. These trades involve ESOP-related activities and market sales.
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹629.6 Cr (+4.7% YoY) and net profit of ₹165.9 Cr (+28.3% YoY) for Q1 FY27.
Dr. Lal PathLabs reported strong Q1 FY27 results with 19.1% revenue growth and 27.2% PAT growth. Strategy remains focused on scientific leadership, patient experience, and operational excellence.
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹797.7 Cr (+19.1% YoY) and net profit of ₹170.5 Cr (+27.2% YoY) for Q1 FY27.
Dr. Lal PathLabs reported strong Q4 FY26 results with 16.6% revenue growth. Focus remains on expansion through 1,100+ new collection centers and high-end diagnostic branding.
Dr. Lal PathLabs reported strong Q4 FY26 revenue growth of 16.6% YoY, driven by volume momentum. The company is focusing on digital transformation and expanding into Tier 3+ markets.
Dr. Lal PathLabs delivered steady growth in Q4 FY26, with revenue rising 16.6% YoY to ₹703 cr. Performance was driven by high sample volumes and expansion into Tier 3+ markets.
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹702.7 Cr (+16.6% YoY) and net profit of ₹132.2 Cr (-15.0% YoY) for Q4 FY26.